Synergistic Effects of Salvianolic Acid B and Puerarin on Cerebral Ischemia Reperfusion Injury
Ischemic stroke (IS) is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. It has been a worldwide critical disease threatening to the health and life of human beings. Despite significant progresses achieved, effective treatment still remains a formidable challenge due to the complexity of the disease. Salvianolic acid B (Sal-B) and Puerarin (Pue) are two active neuroprotectants isolated from traditional Chinese herbs, Salvia miltiorrhiza and Kudzu root respectively, which have been used for the prevention and treatment of IS for thousands of years in China. The activities of two compounds against cerebral ischemia reperfusion injury have been confirmed via various pathways. However, the therapeutic efficacy of any of the two components is still unsatisfied. In the present study, the effect of the combination of Sal-B and Pue on IS was evaluated and validated in vitro and in vivo. The ratio of two compounds was firstly optimized based on the results of CoCl₂ damaged PC12 cells model. The co-administration exhibited significantly protective effect in CoCl₂ induced PC12 cells injury model by reducing ROS, inhibiting apoptosis and improving mitochondrial membrane potential in vitro. Moreover, Sal-B + Pue significantly relieved neurological deficit scores and infarct area than Sal-B or Pue alone in vivo. The results indicated that neuroprotection mechanism of Sal-B + Pue was related to TLR4/MyD88 and SIRT1 activation signaling pathway to achieve synergistic effect, due to the inhibition of NF-κB transcriptional activity and expression of pro-inflammatory cytokine (TNF-α, IL-1β, IL-6). In conclusion, the combination of Sal-B and Pue exerted much stronger neuroprotective effect than Sal-B or Pue alone, which provides a potential new drug and has great significance for the treatment of IS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 23(2018), 3 vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ling, Chengli [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.08.2018 Date Revised 07.12.2018 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules23030564 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281558817 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281558817 | ||
| 003 | DE-627 | ||
| 005 | 20231225031916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules23030564 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0938.xml |
| 035 | |a (DE-627)NLM281558817 | ||
| 035 | |a (NLM)29498696 | ||
| 035 | |a (PII)E564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ling, Chengli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergistic Effects of Salvianolic Acid B and Puerarin on Cerebral Ischemia Reperfusion Injury |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2018 | ||
| 500 | |a Date Revised 07.12.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ischemic stroke (IS) is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. It has been a worldwide critical disease threatening to the health and life of human beings. Despite significant progresses achieved, effective treatment still remains a formidable challenge due to the complexity of the disease. Salvianolic acid B (Sal-B) and Puerarin (Pue) are two active neuroprotectants isolated from traditional Chinese herbs, Salvia miltiorrhiza and Kudzu root respectively, which have been used for the prevention and treatment of IS for thousands of years in China. The activities of two compounds against cerebral ischemia reperfusion injury have been confirmed via various pathways. However, the therapeutic efficacy of any of the two components is still unsatisfied. In the present study, the effect of the combination of Sal-B and Pue on IS was evaluated and validated in vitro and in vivo. The ratio of two compounds was firstly optimized based on the results of CoCl₂ damaged PC12 cells model. The co-administration exhibited significantly protective effect in CoCl₂ induced PC12 cells injury model by reducing ROS, inhibiting apoptosis and improving mitochondrial membrane potential in vitro. Moreover, Sal-B + Pue significantly relieved neurological deficit scores and infarct area than Sal-B or Pue alone in vivo. The results indicated that neuroprotection mechanism of Sal-B + Pue was related to TLR4/MyD88 and SIRT1 activation signaling pathway to achieve synergistic effect, due to the inhibition of NF-κB transcriptional activity and expression of pro-inflammatory cytokine (TNF-α, IL-1β, IL-6). In conclusion, the combination of Sal-B and Pue exerted much stronger neuroprotective effect than Sal-B or Pue alone, which provides a potential new drug and has great significance for the treatment of IS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Salvianolic acid B | |
| 650 | 4 | |a combination | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a ischemia stroke | |
| 650 | 4 | |a puerarin | |
| 650 | 4 | |a synergistic effect | |
| 650 | 7 | |a Benzofurans |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a IL1B protein, rat |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Isoflavones |2 NLM | |
| 650 | 7 | |a Myd88 protein, rat |2 NLM | |
| 650 | 7 | |a Myeloid Differentiation Factor 88 |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Tlr4 protein, rat |2 NLM | |
| 650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Cobalt |2 NLM | |
| 650 | 7 | |a 3G0H8C9362 |2 NLM | |
| 650 | 7 | |a salvianolic acid B |2 NLM | |
| 650 | 7 | |a C1GQ844199 |2 NLM | |
| 650 | 7 | |a cobaltous chloride |2 NLM | |
| 650 | 7 | |a EVS87XF13W |2 NLM | |
| 650 | 7 | |a puerarin |2 NLM | |
| 650 | 7 | |a Z9W8997416 |2 NLM | |
| 700 | 1 | |a Liang, Jianming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ruixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Mou, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaofang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianxin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 23(2018), 3 vom: 02. März |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2018 |g number:3 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules23030564 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2018 |e 3 |b 02 |c 03 | ||